» Articles » PMID: 32161305

Prevalence of Atrophic Gastritis in Southwest China and Predictive Strength of Serum Gastrin-17: A Cross-sectional Study (SIGES)

Overview
Journal Sci Rep
Specialty Science
Date 2020 Mar 13
PMID 32161305
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A hospital-based cross-sectional study in SIGES project was conducted during 2016.5-2017.5 in West China Hospital. It was aimed to observe the prevalence of atrophic gastritis (AG) in southwest China, and assess the diagnostic strength of serum gastrin-17 (G-17) in predicting AG in Chinese population. Asymptomatic healthy controls from health check-up, cancer-free patients with unspecific upper gastrointestinal symptoms, and histologically proven gastric cancer patients were eligible, if serum pepsinogen-I (PG-I), PG-II, and G-17 were detected. AG status was classified by the accredited cutoffs of PG-I (<70 ug/L) and PG-I/II ratio (<3). Totally, healthy controls (n = 9,425), symptomatic patients (n = 671) and gastric cancer patients (n = 305) were simultaneously observed, in which the prevalence of AG in southwest China were estimated as 15.9/1,000, 28.3/1,000, and 55.7/1,000 persons, respectively. The age-specific prevalence of AG in healthy controls showed a significantly uphill trend (p for trend <0.001). Higher level of serum G-17 was significantly associated with increased risk of AG in healthy population (15-30 pmol/L, aOR = 20.67, 95% CI 9.17-46.55; >30 pmol/L, aOR = 314.41, 95% CI 166.10-595.12). Throughout the progression of stomach diseases, the diagnostic strength of serum G-17 for AG showed a downhill trend across more advanced situations. In despite of that, serum G-17 displayed a good performance in predicting AG in the entire cross-sectional population (AUC = 0.92, 95% CI 0.89-0.94; SEN = 85.5%; SPE = 93.2%; LR+ = 12.55; LR- = 0.11). Population in southwest China had intermediate prevalence of AG, while the prevalence was increased over age or disease progression. High level of serum G-17 might be a reliable non-invasive measurement to predict AG in southwest Chinese population.

Citing Articles

A novel nomogram for predicting the morbidity of chronic atrophic gastritis based on serum CXCL5 levels.

Pei B, Sun Q, Zhang Y, Wen Z, Ding W, Wu K BMC Cancer. 2025; 25(1):63.

PMID: 39794766 PMC: 11720569. DOI: 10.1186/s12885-024-13394-0.


Global progress and future prospects of early gastric cancer screening.

Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G J Cancer. 2024; 15(10):3045-3064.

PMID: 38706913 PMC: 11064266. DOI: 10.7150/jca.95311.


infection prevalence declined among an urban health check-up population in Chengdu, China: a longitudinal analysis of multiple cross-sectional studies.

Zou J, Wen M, Huang Y, Chen X, Hu J Front Public Health. 2023; 11:1128765.

PMID: 38089026 PMC: 10711608. DOI: 10.3389/fpubh.2023.1128765.


Analysis of gastrin-17 and its related influencing factors in physical examination results.

Zeng J, Shen Y, Xu S, Yang R Immun Inflamm Dis. 2023; 11(10):e993.

PMID: 37904688 PMC: 10604568. DOI: 10.1002/iid3.993.


Crosstalk between and gastrointestinal microbiota in various gastroduodenal diseases-A systematic review.

Sharma P, Phatak S, Warikoo P, Mathur A, Mahant S, Das K 3 Biotech. 2023; 13(9):303.

PMID: 37588796 PMC: 10425313. DOI: 10.1007/s13205-023-03734-5.


References
1.
Brenner H, Rothenbacher D, Weck M . Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value. Int J Cancer. 2007; 121(12):2782-6. DOI: 10.1002/ijc.22992. View

2.
Song H, Ekheden I, Zheng Z, Ericsson J, Nyren O, Ye W . Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015; 351:h3867. PMC: 4516137. DOI: 10.1136/bmj.h3867. View

3.
Chen X, Schottker B, Castro F, Chen H, Zhang Y, Holleczek B . Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: A ten-year follow-up of the ESTHER cohort study. Oncotarget. 2016; 7(13):17182-93. PMC: 4941379. DOI: 10.18632/oncotarget.7946. View

4.
Ikeda F, Shikata K, Hata J, Fukuhara M, Hirakawa Y, Ohara T . Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol. 2016; 26(12):629-636. PMC: 5121431. DOI: 10.2188/jea.JE20150258. View

5.
Malfertheiner P, Megraud F, OMorain C, Atherton J, Axon A, Bazzoli F . Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5):646-64. DOI: 10.1136/gutjnl-2012-302084. View